TY - JOUR
T1 - Cobra venom factor, an activator of the complement system, enhances the bowel necrosis induced by platelet-activating factor
AU - Llausas-Magana, Eduardo
AU - Hsueh, Wei
AU - Arroyave, Carlos M.
AU - Arroyave, Josefa L.
AU - Torre-Amione, Guillermo
AU - Gonzalez-Crussi, F.
N1 - Funding Information:
This work was supported by NIH grant AM 34574 and a grant from The Children's Memorial Hospital Research Foundation. We are grateful to Mr. Anthony Thomas for the photographic work.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1988
Y1 - 1988
N2 - We have previously produced an experimental model of ischemic bowel necrosis in the rat by injecting platelet activating factor (PAF) (7 μg/kg) into the mesenteric vascular bed. The dose of PAF required to produce necrosis could be reduced to 50% if the animal was pretreated with bacterial endotoxin (lipopolysaccharide) (20 /mgg/rat). The mechanism of this potentiating effect of lipopolysaccharide is nuclear, but activation of the complement system may be one of the contributing factors. To investigate the role of the complement system, we injected cobra venom factor (CVF) (1 unit/kg) to activate the complement system before injection of PAF (2μg/kg) into the superior mesenteric artery. CVF and PAF were also injected separately at the same dosage to other groups of rats. CVF activated the complement system, but by itself did not produce gross necrosis of the bowel. PAF alone caused 3 out of 9 rats treated to develop bowel necrosis. In contrast, combination of the two produced bowel necrosis in all 6 rats thus treated. CVF did not enhance the effects of PAF on hemoconcentration and leukopenia, but aggravated the hypotension caused by PAF. PAF, on the other hand, also enhanced activation of the complement system by CVF. To investigate the specificity of PAF on complement activation, lyso-PAF was used in combination with CVF. It was found that lyso-PAF did not have a significant potentiating effect on CVF-induced complement activation and, by itself, it had no effect on complement activation, blood pressure, white blood cell count or hematocrit. Lyso-PAF, with or without CVF, also failed to produced bowel necrosis. Our results show that: (a) complement activation by itself was not sufficient to cause ischemic bowel necrosis; (b) lyso-PAF was ineffective in causing bowel lesions, while PAF at low doses occasionally induced mild necrotic lesions; (c) PAF enhanced the activation of the complement system by CVF, while lyso-PAF was ineffective; and (d) CVF (which activates complement) potentiated the effect of PAF, to cause bowel necrosis.
AB - We have previously produced an experimental model of ischemic bowel necrosis in the rat by injecting platelet activating factor (PAF) (7 μg/kg) into the mesenteric vascular bed. The dose of PAF required to produce necrosis could be reduced to 50% if the animal was pretreated with bacterial endotoxin (lipopolysaccharide) (20 /mgg/rat). The mechanism of this potentiating effect of lipopolysaccharide is nuclear, but activation of the complement system may be one of the contributing factors. To investigate the role of the complement system, we injected cobra venom factor (CVF) (1 unit/kg) to activate the complement system before injection of PAF (2μg/kg) into the superior mesenteric artery. CVF and PAF were also injected separately at the same dosage to other groups of rats. CVF activated the complement system, but by itself did not produce gross necrosis of the bowel. PAF alone caused 3 out of 9 rats treated to develop bowel necrosis. In contrast, combination of the two produced bowel necrosis in all 6 rats thus treated. CVF did not enhance the effects of PAF on hemoconcentration and leukopenia, but aggravated the hypotension caused by PAF. PAF, on the other hand, also enhanced activation of the complement system by CVF. To investigate the specificity of PAF on complement activation, lyso-PAF was used in combination with CVF. It was found that lyso-PAF did not have a significant potentiating effect on CVF-induced complement activation and, by itself, it had no effect on complement activation, blood pressure, white blood cell count or hematocrit. Lyso-PAF, with or without CVF, also failed to produced bowel necrosis. Our results show that: (a) complement activation by itself was not sufficient to cause ischemic bowel necrosis; (b) lyso-PAF was ineffective in causing bowel lesions, while PAF at low doses occasionally induced mild necrotic lesions; (c) PAF enhanced the activation of the complement system by CVF, while lyso-PAF was ineffective; and (d) CVF (which activates complement) potentiated the effect of PAF, to cause bowel necrosis.
KW - Cobra venom factor
KW - Complement activation
KW - Ischemic bowel necrosis
KW - Lyso-PAF
KW - Platelet activating factor
UR - http://www.scopus.com/inward/record.url?scp=0023879256&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023879256&partnerID=8YFLogxK
U2 - 10.1016/0162-3109(88)90040-9
DO - 10.1016/0162-3109(88)90040-9
M3 - Article
C2 - 3360596
AN - SCOPUS:0023879256
SN - 0162-3109
VL - 15
SP - 31
EP - 37
JO - Immunopharmacology
JF - Immunopharmacology
IS - 1
ER -